Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;12(2):226-239.
doi: 10.1002/ueg2.12554. Epub 2024 Feb 19.

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives

Jian-Jian Chen  1 , Zhi-Cheng Jin  1 , Bin-Yan Zhong  2 , Wenzhe Fan  3 , Wei-Hua Zhang  1 , Biao Luo  1 , Yu-Qing Wang  1 , Gao-Jun Teng  1 , Hai-Dong Zhu  1
Affiliations
Review

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives

Jian-Jian Chen et al. United European Gastroenterol J. 2024 Mar.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.

Keywords: combined modality therapy; hepatocellular carcinoma; immune checkpoint inhibitors; locoregional therapy; molecular targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. 10.3322/caac.21708 - DOI - PubMed
    1. Reig M, Forner A, Rimola J, Ferrer‐Fàbrega J, Burrel M, Garcia‐Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. 10.1016/j.jhep.2021.11.018 - DOI - PMC - PubMed
    1. Bureau of Medical Administration NHCotPsRoC. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition). Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol. 2022;30(4):367–388. - PubMed
    1. Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. 10.1159/000509424 - DOI - PMC - PubMed
    1. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181–223. 10.1159/000514174 - DOI - PMC - PubMed

Substances